Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Idenix Pharmaceuticals, a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, has reported positive in-vitro data for IDX320, an HCV protease inhibitor, demonstrating potent and selective antiviral activity in multiple genotypes, or strains, of the virus.
Subscribe to our email newsletter
Idenix Pharmaceuticals said that the positive pharmacokinetic profile defined in preclinical studies was confirmed by interim Phase I clinical data in healthy volunteers. Additional data presented demonstrated that a combination of three Idenix drug candidates, including IDX320, with different mechanisms of action produced strong synergy in vitro. These data support the evaluation of direct-acting antiviral (DAA) combination regimens for the treatment of HCV.
IDX320 is a potent inhibitor of NS3/4A proteases from genotypes 1a, 1b, 2a and 4a (IC(50) values from 0.8 to 1.9nm), as well as from genotype 3a (IC(50)=23nm).
Reportedly, the signature mutation observed in-vitro was D168V, consistent with other macrocyclic inhibitors. This mutation had reduced replication fitness and was susceptible to treatment with interferon as well as other classes of DAAs.
After single 2mg/kg oral doses of IDX320 in two animal species, favorable bioavailability and a long plasma half-life were observed, with substantial plasma concentrations 24 hours post dose. These preclinical data were confirmed in orally-dosed healthy volunteers (n=6) receiving a single 200mg tablet.
Further, no significant in-vitro inhibition of human drug metabolizing enzymes, CYP450s and UGT1A1, by IDX320 suggests low potential for drug-drug interactions in patients.
Double and triple combination in-vitro studies of Idenix’s HCV direct-acting antiviral drug candidates from different HCV drug classes, including IDX184 (a nucleotide inhibitor), IDX320 (a protease inhibitor), IDX375 (a non-nucleoside inhibitor) and a prototype Idenix NS5A inhibitor, were reported.
Data demonstrated that double combinations (IDX320 with IDX184, IDX375 or NS5A inhibitor) resulted in additive to mildly synergistic effects after 3 days of treatment in vitro. Furthermore, triple combinations, especially those including agents from three different HCV drug classes (IDX184/IDX320/IDX375 or IDX184/IDX320/NS5A inhibitor), demonstrated the strongest synergy in vitro. Similar results were observed over 14-days of treatment with no evidence of viral breakthrough or cellular cytotoxicity.
David Standring, executive vice president of biology at Idenix, said: “With the in-vitro potency and favorable pharmacokinetic profile seen to date combined with the potential for once-daily dosing and multi-genotypic coverage, we believe IDX320 could offer improvements over other protease inhibitors currently in development.
“The Phase I single and multiple ascending dose clinical study in healthy volunteers is now complete, and we look forward to advancing IDX320 into a three-day proof-of-concept study expected to begin in the second quarter.”
Jean-Pierre Sommadossi, CEO of Idenix, said: “The in-vitro combination data presented today continue to support our belief that the future of HCV treatment will be a combination of direct-acting antivirals from different drug classes. We are pursuing a drug development strategy to achieve that goal.”